New combo may offer better option for Hard-to-Treat colorectal cancer
NCT ID NCT07362836
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new drug combination (fruquintinib plus chemotherapy) works better than the current standard (bevacizumab plus chemotherapy) for people with a specific type of advanced colorectal cancer that has a RAS mutation. About 224 adults aged 18 to 75 will be randomly assigned to one of the two treatments. The main goal is to see how long patients live without their cancer getting worse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?